We reasoned that the major traits of the mutation carriers, hypertriglyceridemia, fatty liver disease, and T2D, are the consequence of altered hepatic glucose and lipid metabolism, and embarked on characterizing the hepatic function of Dyrk1b. Here, DYRK1B is linked to fatty liver disease.